Sucampo Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 2.02%159.260.7%$1174.61m
PFEPfizer Inc. 1.22%34.810.9%$1077.23m
MRKMerck & Co., Inc. 3.30%75.540.7%$887.74m
BMYBristol-Myers Squibb Co. 1.89%61.571.0%$850.37m
ABBVAbbVie, Inc. 1.13%107.911.9%$724.53m
LLYEli Lilly & Co. 1.60%210.241.1%$646.08m
AZNAstraZeneca Plc 0.43%48.271.2%$488.45m
GSKGlaxoSmithKline Plc 1.02%35.270.2%$275.23m
NVSNovartis AG 0.58%84.500.2%$167.30m
SNYSanofi 0.38%46.770.2%$163.79m
VTRSViatris, Inc. 0.07%13.920.0%$134.61m
VERUVeru, Inc. 3.08%12.710.0%$124.78m
KALVKalVista Pharmaceuticals, Inc. -0.76%30.650.4%$98.88m
NVONovo Nordisk A/S -0.01%69.600.1%$91.35m
RPRXRoyalty Pharma Plc 5.62%44.930.2%$84.16m

Company Profile

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.